2021
- 01.14.2020 - Lypro Biosciences congratulates ABIONYX on initiation of Phase 2a clinical trial of CER-001
2017
- 11.08.2017 - Cerenis Therapeutics Acquires Lypro Biosciences
2015
- 05.01.2015 - Lypro Biosciences Announces the Commercial Launch of Ambigent™, an Antifungal Reagent for High Value Cell Cultures
2012
- 08.20.2012 - Lypro Biosciences Announces Late-Breaker Presentation at 52nd ICAAC Annual Meeting
2011
- 12.30.2011 - Lypro Biosciences Expands Global Patent Portfolio
- 11.18.2011 - Lypro Demonstrates Cell Specific Delivery of Targeted NanoDisk for Mantle Cell Lymphoma
- 11.07.2011 - Lypro Biosciences to Present at Life Science Summit 2011
- 07.25.2011 - Japanese Patent Office Allows NanoDisk Patent Claims
- 02.14.2011 - Peter Calcott, Ph.D. Joins Lypro to Guide Manufacturing Strategy
2010
- 11.02.2010 - Lypro Biosciences Announces Issuance of US Patent for NanoDisk Drug Delivery Platform
- 10.29.2010 - Lypro Biosciences Awarded Qualifying Therapeutic Discovery Grant for NanoDisk Platform Drug Delivery Technology
- 10.15.2010 - Lypro Biosciences Recruits Stephen F. Carroll, Ph.D. to Lead Drug Development
- 08.27.2010 - Lypro Biosciences Secures Additional Financing to Support NanoDisk Product Pipeline Development
- 07.20.2010 - Indian Patent Office Grants Patent Claims for NanoDisk Technology
- 06.29.2010 - Lypro Biosciences Receives Competitively Renewed Phase II NIH SBIR Grant to Develop Novel Antifungal
- 01.26.2010 - Lypro Biosciences Awarded Phase I NIH SBIR Grant to Develop a Targeted Therapy for Mantle Cell Lymphoma